Pks 13 inhibitors—a promising target for future antitubercular agents-Reference-Cited by-同舟云学术

Pks 13 inhibitors—a promising target for future antitubercular agents

Published:2023-06-17 Issue:8 Volume:32 Page:1574-1588
ISSN:1054-2523
Container-title:Medicinal Chemistry Research
language:en
Short-container-title:Med Chem Res

Author:

Uppumavuluri Naga Tejaswi,Krovvidi Sri Ram,Mailavaram Raghu Prasad^ORCID,Mohanty Sujit Kumar,Deb Pran Kishore,Venugopala Katharigatta N.

Publisher

Springer Science and Business Media LLC

Subject

Organic Chemistry,General Pharmacology, Toxicology and Pharmaceutics

Link

https://link.springer.com/content/pdf/10.1007/s00044-023-03107-w.pdf

Reference87 articles.

1. Chakaya J, Khan M, Ntoumi F, Aklillu E, Fatima R, Mwaba P, et al. Global Tuberculosis Report 2020—Reflections on the Global TB burden, treatment and prevention efforts. Int J Infect Dis. 2021;113:S7–12. https://doi.org/10.1016/j.ijid.2021.02.107.

2. Cheng D, Ming H, Wanru G, Wenjuan H, Xiaomeng L, Shuting W, et al. Prevalence trends of latent tuberculosis infection at the global, regional, and country levels from 1990–2019. Int J Infect Dis. 2022;122:46–62. https://doi.org/10.1016/j.ijid.2022.05.029.

3. Dean AS, Tosas Auguet O, Glaziou P, Zignol M, Ismail N, Kasaeva T, et al. 25 years of surveillance of drug-resistant tuberculosis: achievements, challenges, and way forward. Lancet Infect Dis. 2022;22:e191–6. https://doi.org/10.1016/S1473-3099(21)00808-2.

4. World Health Organization. (2019). WHO consolidated guidelines on drug-resistant tuberculosis treatment. World Health Organization. https://apps.who.int/iris/handle/10665/311389.

5. Xu L, Zhang F, Xu C, Liu KG, Wu W, Tian YX. Is the prophylactic use of hepatoprotectants necessary in anti-tuberculosis treatment? Chemotherapy. 2017;62:269–78. https://doi.org/10.1159/000465515.